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ABSTRACT 
The subtle hypoxia underlying chronic cardiovascular disease is an attractive target for PET 
imaging, but the lead hypoxia imaging agents 64CuATSM and 18FMISO trapped only at 
extreme levels of hypoxia and hence are insufficiently sensitive for this purpose. We have 
therefore sought an analog of 64CuATSM better suited to identify compromised but 
salvageable myocardium, validated using parallel biomarkers of cardiac energetics 
comparable to those observed in chronic cardiac ischemic syndromes. 
Methods: Rat hearts were perfused with aerobic buffer for 20 min, followed by a range of 
hypoxic buffers (using a computer-controlled gas mixer) for 45 min. Contractility was 
monitored by intraventricular balloon, energetics by 31P NMR spectroscopy, lactate and 
creatine kinase release spectrophotometrically, and HIF1 by Western blotting.  
Results: We identify a key hypoxia threshold at a 30% buffer O2 saturation which induces a 
stable and potentially survivable functional and energetic compromise: LV developed 
pressure was depressed by 20%, and cardiac phosphocreatine was depleted by 65.5 ± 14% 
(p<0.05 vs control), but ATP levels were maintained. Lactate release was elevated (0.21 ± 
0.067 versus 0.056 ± 0.01 mmol/L/min, p<0.05), but not maximal (0.46 ± 0.117 mmol/L/min), 
indicating residual oxidative metabolic capacity. HIF1 was elevated, but not maximal. At 
this key threshold, 64CuCTS selectively deposited significantly more 64Cu than any other 
tracer we examined (61.8 ± 9.6% injected dose versus 29.4 ± 9.5% for 64CuATSM p<0.05).  
Conclusion: The hypoxic threshold which induced survivable metabolic and functional 
compromise was 30% O2. At this threshold, only
 64CuCTS delivered a hypoxic:normoxic 
contrast of 3:1, and it therefore warrants in vivo evaluation for imaging chronic cardiac 
ischemic syndromes. 
 
Keywords- Cardiac hypoxia, PET, NMR, bioenergetics, Cu-ATSM, bis(thiosemicarbazones) 
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INTRODUCTION 
Hypoxia is a major factor in the pathology of cardiac ischemia. It is an important factor in the 
etiology of microvascular disease and cardiac hypertrophy, the prime determinant of the 
progression to heart failure, and the driver for compensatory angiogenesis 1-3. In 
microvascular disease, while gross perfusion measured by MRI or scintigraphy may appear 
normal, the myocardium is hypoxically compromised at the cellular level 4.  This makes it an 
extremely difficult condition to diagnose, currently assigned by exclusion of other pathologies 
5. In hypertrophic myocardium, perfusion is also often “normal”, but increased cell size, loss 
of t-tubules, and scar means that increased diffusion distances critically limit oxygen delivery 
to mitochondria 6, 7. To accurately characterise these conditions, imaging disparities between 
supply and demand for blood flow (ischemia), or O2 (hypoxia), would be a potentially more 
useful approach than measuring poor perfusion per se 8, but as yet, there are no 
methodologies sufficiently sensitive or specific for this purpose 9, 10. 
The PET tracer 64CuATSM (R1=R3=R4=R6=Me, R2=R5=H, Fig 1), exhibits rapid first pass 
uptake and fast clearance from normoxic tissues 11 and blood 12, and rapid retention in 
hypoxic tissues to generate excellent images of tissue hypoxia within minutes. 
Experimentally, tissue 64Cu accumulation from 64CuATSM has been demonstrated only in 
extreme models of acute hypoxia and ischemia in isolated perfused hearts, and in regionally 
occluded canine myocardium in vivo 13, 14, appearing to have a hypoxia-selective threshold of 
1mm Hg or lower 11, 15. While this degree of hypoxia is compatible with the survival and 
radio-resistance of cancer cells, for which it was designed, it is too severe for the long-term 
survival of cardiac myocytes (normal cardiac mitochondrial pO2 is 10-35 mm Hg) 
16. In the 
one very small (seven patient) cardiac clinical trial that has been performed to date using 
62CuATSM, 62Cu accumulation was only visualised in the myocardium of one patient with 
unstable angina, despite four of those patients exhibiting increased regional 18FDG uptake 
12. Thus, while CuATSM can be used to selectively identify the extreme acute hypoxia 
commonly induced in experimental models, it seems insufficiently sensitive to detect the 
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subtle hypoxia characterising the chronic cardiac ischemic syndromes that are currently 
difficult to identify 9.  
 
The fundamental challenge, therefore, is to identify complexes which deposit their 
radiocopper payload within the myocardium at less extreme levels of hypoxia where its 
biochemistry is perturbed, but remains potentially salvageable. We reason that this target 
hypoxia “threshold” would be the point where there remains a degree of metabolic flexibility: 
a compromised but functional capacity for oxidative metabolism, but with sufficient ATP 
turnover to maintain ionic homeostasis and cellular integrity 9. We have therefore performed 
a series of hypoxia titrations in the isolated heart to determine where this threshold lies using 
a panel of biochemical and biophysical assays. We then use a recently developed gamma 
detection array 17 to identify analogs of 64CuATSM exhibiting greater sensitivity to hypoxia at 
this more relevant threshold. 
 
MATERIALS AND METHODS 
Reagents and Animals 
All reagents were purchased from Sigma unless otherwise stated.  Gases were supplied by 
BOC. Desired gas mixtures (O2/N2/CO2) were achieved using a GSM-3 gas mixer (CWE 
Inc). 
 
Male Wistar rats (275-300 g, Harlan), fed ad libitum, were used for all experiments. Animal 
procedures were in accordance with the Animals (Scientific Procedures) Act UK (1986). 
 
Experimental Protocol 
64Cu was produced and used to radiolabel 2,3-butanedione bis (thiosemicarbazone) (ATS), 
diacetyl-bis(N4-ethylthiosemicarbazone) (ATSE), 2,3-butanedione bis(N4-
methylthiosemicarbazone) (ATSM) and 2,3-pentanedione bis(thiosemicarbazone) (CTS) as 
previously described 17. 
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Rats (n = 6/group) were anesthetized with Sagatal (100 mg ip) and heparinized (200 IU ip), 
their hearts excised and cannulated in the Langendorff mode 18. Hearts were perfused at 
constant flow (to simplify pharmacokinetic modeling) of 14 ml/min with a modified Krebs-
Henseleit buffer (KHB) described previously 17, gassed with 95% O2/5% CO2 gas mixture, 
and contractile function was measured with a left ventricular balloon. Perfusion pressure was 
monitored by a pressure transducer in the arterial line. Hearts were paced at 300 beats/min 
throughout. 
 
After 20 minutes, perfusate delivery was switched to a second reservoir containing KHB 
equilibrated with a gas mixture containing either 95%, 40%, 30%, 20%, 10% or 0% O2, 
balanced with N2 and 5% CO2 (for pH buffering), delivered by a gas mixer. 1 ml aliquots of 
coronary effluent were collected at regular intervals, and analysed for lactate content (YSI 
2300 STAT Plus™ lactate analyser) to identify the onset of anerobic glycolysis, and creatine 
kinase content to monitor tissue necrosis. At the end of each experiment, hearts were snap-
frozen in liquid nitrogen prior to Western blotting for HIF1. 
 
31P Magnetic Resonance Spectroscopic Analysis (MRS) 
Hearts were cannulated and inserted into a 15 mm glass MRS tube which was then placed 
in a custom-built MRS probe, as previously described 19. 31P MRS spectra were acquired on 
a Bruker Avance III 9.4T spectrometer using a 15 mm 31P/1H birdcage coil 20. Shimming was 
performed on the 1H lineshape of water (FWHM < 20 Hz). 31P spectra were acquired with a 
pulse-acquire sequence using a 60o flip angle, repetition time of 3.8 s and 64 scans (4 
minutes per spectrum). The peak area of each metabolite was normalized to that of 
phosphocreatine (PCr) during normoxia. 
 
Profiling of Radiotracer Retention and Elution 
In parallel groups of hearts, radiotracer uptake and pharmacokinetics were monitored using 
a custom built “triple gamma detector system” 17, consisting of three orthogonally positioned 
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lead-shielded NaI detectors interrogating the arterial input line, the heart, and the venous 
outflow lines respectively, each connected to a modified GinaSTAR™ instant thin layer 
chromatography system (Raytest Ltd).  100 µl boluses containing 1 MBq radiotracer were 
injected into the arterial line after 10 minutes of normoxia, and 5 and 25 minutes of hypoxia. 
Time-activity curves generated by the GinaSTAR™ were imported into MATLAB® 
(MathWorks®). Data were decay-corrected and normalized to the maximum value of each 
group. Tissue retention was calculated as the residual activity in the heart 20 minutes post-
injection as a percentage of the peak activity (% injected dose, %ID), as previously 
described 21. 
 
Western Blotting 
Hearts were homogenized in 10 ml of homogenization buffer / g tissue (100 mM Tris pH 7.4, 
2 mM sodium vanadate, 5 mM sodium fluoride, 1 x protease inhibitor cocktail tablet / 50 ml, 
4oC). Equal volumes of homogenate and 2 x sodium dodecyl sulphate sample buffer were 
mixed before being loaded and separated by molecular weight using SDS-PAGE on a 10% 
polyacrylamide gel. Proteins were transferred to PVDF membranes (0.45 µm; GE 
Healthcare) using semi-dry blotting (Biorad). Blots were incubated for 2 hours at room 
temperature with hypoxia inducible factor (HIF-1α) antibody (rat polyclonal 5 µg/ml; Abcam). 
After incubation with HRP-labeled secondary antibodies, blots were developed using 
enhanced chemiluminescence (Amersham Pharmacia Biotech), with GAPDH as a loading 
control. HIF-1α and GAPDH expression were quantified through film-scanning and 
densitometry using Quantity One software (Biorad), with HIF-1α normalized to GAPDH. 
 
Statistical Analysis 
Analyses were performed using GraphPad Prism® (GraphPad Software Inc). All values are 
expressed as the mean±SD. A paired t-test was used for all pair-wise comparisons, and one 
way ANOVA with the Bonferroni correction for multi-way comparisons. Dunnett’s post 
analysis test was applied when multiple comparisons were made to a control group.
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RESULTS 
All tracers examined deposited increasing amounts of radiocopper in the myocardium with 
increasingly severe hypoxia (Fig 2). Hypoxia selectivity was apparent within 5 minutes of 
onset (Fig 2a), with significant 64Cu retention in hearts injected with 64CuCTS with KHB 
equilibrated with 30% O2 (40.9 ± 4.6% ID versus 13.7 ± 3.1% pre-hypoxia p<0.05), with an 
EC50 value of 32.1% O2. While the other tracers also exhibited hypoxia selectivity, they were 
less sensitive; 64Cu ATSM and 64Cu ATSE were only selective at the 20% O2 threshold (31.3 
± 1.42 and 39.34% ID, EC50 values of 18.9 and 22.9% O2 respectively), while 
64CuATS was 
only selective at the 10% O2 threshold (34.7 ± 12.7% ID, EC50 7.4% O2). The same 
selectivities were evident after 25 minutes (Figure 2b), although the absolute amount of 
radiocopper deposition in each case was greater. 64CuCTS was the only tracer to selectively 
deposit radiocopper in the heart at 30% O2 (61.8 ± 9.6% versus 15.8 ± 3.8% ID in normoxic 
hearts (p<0.05), EC50 32% O2), and consistently more than 
64CuATSM under all hypoxic 
conditions. The selectivity profiles of 64CuATSM, 64CuATSE and 64CuATS were largely 
similar (EC50 values of 25.2, 25.1 and 22.2% O2 respectively), although 
64CuATS deposited 
significantly more 64Cu than 64CuATSM at 0% O2 (78 ± 7.2% versus 63.4 ± 11.5; p<0.05). 
 
The critical threshold for decreasing LVDP within 5 minutes was 20% O2, (to 68 ± 14 mm Hg 
from a pre-hypoxia 145 ± 12 mm Hg; p<0.05, Fig 3a), although perfusion pressure and 
LVEDP were unaffected. Perfusion with 30% O2 KHB elevated LVEDP above pre-ischemic 
values after 25 minutes (36 ± 8 versus 5 ± 3 mm Hg; p<0.05), while perfusion pressure was 
only elevated within this timeframe by completely anoxic KHB (112 ± 12 versus 73 ± 9 mm 
Hg; p<0.05).  
 
Representative 31P NMR spectra from a heart perfused with 0% O2 KHB are shown in fig 4A. 
PCr was depleted by ~20 minutes of hypoxia, with a concomitant increase in inorganic 
phosphate (Pi). Sugar phosphates became apparent within 8 minutes, and by 25 minutes, 
ATP levels were compromised.  30% O2 KHB decreased cardiac PCr within 5 minutes (to 
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65.5 ± 14% of pre-hypoxia; p<0.05, Fig 4B), while PCr was only compromised by 40%O2 
after 25 minutes (to 43.4 ± 1.4%; p<0.05).  ATP levels were unaffected by 30% O2 KHB, but 
were depleted by 20% O2 KHB (from 66.8 ± 20% to 41.8 ± 17%; p<0.05, Fig 4C); perfusion 
with more hypoxic buffers achieved no greater degree of ATP loss. Sugar and inorganic 
phosphates were not elevated by hypoxia after 5 minutes, but accumulated after 25 minutes 
perfusion with 20% O2 (116 ± 37% versus 60 ± 18% and 49.8 ± 22.2% versus 13.8 ± 10.3% 
respectively; p<0.05). While lactate washout was evident after 25 minutes of perfusion with 
30% O2 KHB, (0.21 ± 0.07 versus 0.01 ± 0.02 nmol during normoxia; p<0.05 (Fig 5A), it 
increased further with 20% O2 KHB to a near-maximal value of 0.46 ± 0.11 (p<0.05). There 
was no evidence of creatine kinase leakage in any experimental group (data not shown). 
HIF-1GAPDH expression was elevated after 25 minutes of 30% O2 KHB (0.278 ± 0.064 
versus normoxic 0.175 ± 0.047; p<0.05, Fig 5B), rising to a maximum of 0.61 ± 0.08 with 0% 
O2 KHB.  
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DISCUSSION 
We recently demonstrated that 64CuCTS and its analog 64CuATS exhibit significantly greater 
hypoxia selectivity than the current lead compound 64CuATSM in hearts perfused with 
hypoxic (0% O2) buffer 
17. While a promising first step in the screening process, the key to 
the progression of this class of compounds is to identify complexes selective for levels of 
hypoxia which correlate with survivable (and treatable) cardiac disease 9, 10. The relative 
sensitivities of these complexes to pathophysiologically relevant degrees of cardiac hypoxia 
were unknown. In this study, we identify a key hypoxic threshold that induces the major 
hallmarks of compromised but salvageable myocardium, which are: depressed contractile 
function, compromised PCr levels (but stable ATP levels), elevated HIF-1expression, and 
increased but not maximal lactate washout (indicating residual oxidative reserve). At this 
threshold, achieved by perfusion with KHB saturated with 30%O2, we demonstrate that 
64CuCTS is the only complex among the four evaluated that provides a hypoxic:normoxic 
tissue contrast which would be exploitable for PET imaging 9. 
Our approach, of identifying parallel biomarkers of biochemical compromise to correlate 
against tracer uptake circumvents the difficult problem of describing tracer uptake in terms of 
absolute (and potentially arbitrary) intracellular oxygen concentrations, which are not only 
difficult to determine, but would also vary in relevance dependent upon oxygen demand, 
cardiac workload, and experimental model 16. It also allows an immediate bioenergetic 
interpretation of the relevance of increased cardiac tracer retention, which is arguably 
translatable from the Langendorff perfused heart to the clinical situation.  While changes in 
cardiac energetics can be quantified by 31P spectroscopic imaging in clinical MR systems, 
the technical capacity and infrastructure to do so is not widespread, requires significant 
expertise, long acquisition times, and results in images of poor spatial resolution. Correlating 
PET tracer uptake with these key changes in cardiac energetics could therefore provide the 
same biochemical insight as 31P MR spectroscopic imaging, but exploit a technically simpler 
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imaging approach with significantly greater temporal and spatial resolution (typical voxel 
sizes for clinical 64Cu PET are 65 mm3 22, compared to 560 mm3 for 31P MRI at 3T) 23.  
We demonstrate that perfusion of hearts with 30% O2 saturated KHB significantly depleted 
PCr, but was sufficient to maintain intracellular ATP and a degree of contractility. These 
characteristics mirror the reductions in PCr:ATP ratio previously demonstrated by 31P MRS 
in patients with heart failure 24,25 and hypertrophic cardiomyopathy 26, and correlate with 
declining left ventricular ejection fraction and increased mortality 27. While moderate 
depletion of cardiac ATP has also been observed in patients diagnosed with hypertrophied 
and failing myocardium 28, we used a less severe experimental threshold where PCr levels 
were compromised, but ATP levels were maintained to provide a more sensitive means of 
screening for diagnostically relevant hypoxia-selective complexes. Crucially, while 30% O2 
KHB increased lactate release by the heart, the rate of lactate washout only became 
maximal when hearts were perfused with KHB equilibrated with 20% O2 and below, 
suggesting that at 30% O2 there was still an aerobic metabolic reserve. At this key threshold, 
therefore, cardiac energetics and contractile function were compromised, but there was 
residual oxidative metabolism (and by inference mitochondrial function), suggesting that this 
degree of hypoxia would be sustainable chronically, making it a reasonable model of chronic 
cardiac ischemia.  
30% O2 was also the threshold for increased intracellular HIF-1. As the key regulator of 
hypoxic gene expression, HIF-1 is responsible for numerous acute and chronic adaptive 
responses to tissue hypoxia, ranging from elevated glucose uptake and altered calcium 
handling to cardiac remodelling 29, cardiomyopathy 30, microvascular disease 31 and heart 
failure 32, while chronic activation of HIF-1 in animal models leads to progressive heart 
failure and premature death 33. Elevated HIF-1 was therefore a prerequisite for the 
threshold against which to evaluate our tracers. There is currently no non-invasive method 
for measuring intracellular HIF-1; a hypoxia-specific imaging agent which correlates with 
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the onset of hypoxia-dependent HIF-1 stabilization, such as we identify in 64CuCTS, is 
therefore a potentially useful development. 
While our isolated heart model is ideal for establishing basic structure-activity relationships 
of new tracers, it is limited in that it cannot inform upon other important pharmacokinetic 
factors like tracer metabolism. Hueting et al. have recently suggested in this Journal that the 
biodistribution and pharmacokinetics of 64Cu-acetate in tumour-bearing mice is similar to that 
of 64Cu-ATSM when assessed after 2 or 16 hours, and that 64Cu-acetate exhibits hypoxia 
selectivity in cultured cancer cells, suggesting that Cu-bis(thiosemicarbazone) complexes 
dissociate quickly in vivo, and that the resultant biodistribution observed by PET is that of 
free copper, questioning the validity of 64CuATSM as a hypoxia tracer 34. We and other 
groups have observed no such non-specific uptake up of ionic 64Cu2+ salts in normoxic or 
hypoxic myocytes in culture 15, CHO cells 35, or in isolated buffer perfused hearts 17, 21. The 
wide variation in pharmacokinetics and early biodistributions that the different 
bis(thiosemicarbazone) ligands have been shown to display, some being hypoxia selective 
(ATSM, ATS, CTS etc.) and some not (PTSM, GTSM), some crossing the blood-brain barrier 
(GTSM, PTSM, ATSM etc.) and some not (ATS)36,37, would also argue against a common 
non-selective mechanism of early tissue uptake. If such a non-selective uptake mechanism 
does exist, it is likely dependent on tracer metabolism, and late recirculation of 64Cu2+ in 
copper transport proteins.  We have recently shown that 64CuATSM, 64CuCTS and 64CuATS 
all rapidly wash out of normoxic myocardium in rats in vivo to a stable low level within 5 
minutes of injection, with no secondary “creep” of non-specific cardiac accumulation due to 
recirculation in the ensuing 30 minutes of imaging 17, and no significant 64Cu retention in 
healthy myocardium by biodistribution after 90 minutes. If secondary recirculation of 64Cu 
occurs at later time points, the time between injection and imaging, and the relative in vivo 
stability of these complexes would be an important consideration in their use and 
interpretation. Our study and many others which precede it 14, 17, 21 highlight the rapid hypoxia 
selectivity and tissue clearance of these tracers (within 5 minutes from normoxic 
12 
 
myocardium both ex vivo, and in vivo)17, 38. We would therefore suggest that the rapid 
kinetics of these tracers could be exploited to minimise the potential impact of metabolism 
and recirculation by keeping imaging times short.  
 
We have used 64Cu in these experiments because its 12 hour half life allows us to perform 
several experiments from each batch. However, its half life is not ideal in terms of patient 
exposure, and with a positron yield of only 17.8%, nor is its dosimetry. In contrast, 62Cu 
production does not require a cyclotron, has a half life of only 9.74 min and a 98% positron 
yield. The rapid kinetics that these tracers display would be very well suited to exploiting the 
dose-limiting advantages of 62Cu radiolabelling clinically. We have employed isolated 
perfused hearts in this study because the model allows the accurate and reproducible 
induction of a range of hypoxic severity which would not be possible (or survivable or 
measurable) in vivo. It should of course be noted that tracer pharmacokinetics may be 
different in blood than in aqueous solution, and that the relationship between cardiac 
workload, arterial blood supply and tracer retention are likely to differ from that in vivo. We 
have, however, demonstrated the relative hypoxia selectivities of these tracers perfused 
under the same conditions, and 64CuCTS appears to be a significant improvement upon 
64CuATSM in terms of hypoxia sensitivity. 
 
We are currently unable to explain fully why 64CuCTS exhibits better selectivity for low grade 
hypoxia than 64CuATSM. Previous reports have suggested that hypoxia selectivity might be 
primarily governed by redox potential, yet CuATS, CuCTS, CuATSM and CuATSE all have 
the same redox potential (-0.59V versus Ag/AgCl35) and different hypoxia selectivities. It 
therefore appears that while redox potential imparts hypoxia selectivity generally (the non-
hypoxia selective tracer CuPTSM has a lower redox potential of -0.51V), subtle modification 
of redox potential is not the only route by which hypoxia selectivity can be fine tuned. We 
previously demonstrated that decreasing tracer lipophilicity increased tracer fast clearance 
rate, and improved hypoxic/normoxic contrast over CuATSM17 (the logP values of CuATSE, 
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CuATSM, CuCTS and CuATS are 2.34, 1.61, 1.01 and 0.35 respectively 21, 35). There is a 
limit to this tactic, however, since CuATS, which has the lowest lipophilicity, provided no 
further gain in hypoxia sensitivity at the 30% threshold. We speculate that the subtle balance 
between redox potential, lipophilicity and steric hindrance of redox and ligand exchange 
reactions governs residence time in the cell (and/or its intracellular localisation), and 
determine the rate at which each complex is reduced, reoxidised and dissociated to release 
its payload.  
  
CONCLUSION 
Hypoxia imaging has the capacity to augment current techniques for identifying viable but at-
risk myocardium. Diffuse hypoperfusion associated with non-compensated hypertrophy or 
microvascular disease is currently difficult to diagnose by imaging perfusion; specifically 
imaging the resultant hypoxia by PET may be a useful alternative approach. While 
64CuATSM seems insufficiently sensitive to target myocardium compromised by such low- 
level survivable hypoxia, we identify 64CuCTS as a potentially more suitable PET tracer in 
this regard. 
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FIGURE LEGENDS 
Figure 1: General structure of the bis(thiosemicarbazones). 64CuATS: R1=R2=CH3, R
3=R4=H; 
64CuATSM=R1=R2=R3=CH3, R
4=H; 64CuCTS=R1=C2H5, R
2=CH3, R
3=R4=H;  64CuATSE: 
R1=R2= R3=R4=CH3 
Figure 2: The relationship between hypoxic buffer perfusion and 64Cu radiotracer uptake.  
Data (mean n=6±SD), represent cardiac 64Cu retention from each tracer for 64CuCTS (closed 
triangles), 64CuATS (open circles), 64CuATSE (open squares), and 64CuATSM (closed 
triangles) as a percentage of injected dose 10 minutes after injection after (A) 5 minutes and 
(B) 25 minutes hypoxia. *significantly different from pre-hypoxic control values (p<0.05).  
Figure 3: The relationship between hypoxic buffer perfusion and cardiac contractility and 
haemodynamics. Data (mean n=6±SD) represent changes in left ventricular developed 
pressure (LVDP), left ventricular end diastolic pressure (LVEDP) and perfusion pressure 
(PP), after (A) 5 minutes and (B) 25 minutes hypoxia. *significantly different from pre-hypoxic 
values (p<0.05). 
Figure 4:  (A) Representative 31P NMR spectra showing the changes in cardiac energetics 
during perfusion with 0% O2 buffer. (B and C): The relationship between hypoxic buffer 
perfusion and cardiac energetics. Data mean (n=6±SD) represent changes in 
phosphocreatine (PCr, closed triangles), ATP (open triangles), inorganic phosphate (Pi, 
open squares), and sugar phosphates (closed circles) after 5 minutes and 25 minutes 
hypoxia. *significantly different from pre-hypoxic values (p<0.05). 
Figure 5: (A) The relationship between hypoxic buffer perfusion and lactate washout after 5 
minutes (closed circles) and 25 minutes (open squares) of hypoxia, and (B) HIF1 
expression at the end of each perfusion protocol. Data (mean n=6±SD), *significantly 
different from pre-hypoxic values (p<0.05).  
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